• by bcarlson@marketresearch.com
  • February 3 2014

Five Companies Dominate Molecular Diagnostics

Five Companies Dominate Molecular Diagnostics

Sixty Percent of the molecular diagnostics market is owned by five companies, according to our latest six-month market update in molecular diagnostics.  Roche leads, and the rest of the names won’t suprise: BD, Abbott, Hologic and Qiagen.  We think top-tier molecular diagnostics companies operating within the market will continue to dominate due to their global reach and multi-segment participation.  Simply put, they have the resources to play in all the fields, and they can reach emerging markets faster than smaller concerns. Further, as in vitro diagnostics (IVD) markets in North America and Europe offer little growth opportunities for the vast number of tests, the top tier of the molecular diagnostics market has invested in molecular and personalized medicine testing and also has reinforced international connections.  

Our recent report, The World Market for Molecular Diagnostics Update, notes that while the names of these molecular diagnostics companies dominating the industry have not changed extensively in recent years, their revenue growth rates have. High growth has shifted to innovators, while molecular diagnostics industry leaders are seeing flatter revenues.

 “Roche holds the number one market position but growth is slowing,”  said Shara Rosen, author of the report.  “Roche Diagnostics once earned close to double digit revenue growth in its molecular test business.  This has slowed in the last two years as the company is conducting a major reorganization and reported that it will phase out its 454 Life Science unit by 2016.”

In vitro diagnostics veterans Becton Dickinson, Gen-Probe (now part of Hologic), Abbott Diagnostics, and Siemens Healthcare hold their own in a highly competitive healthcare market environment, while newcomers Meridian Biosciences and GenMark have made gains with user-friendly infectious disease tests. Meanwhile Pharma specialist Novartis has bailed out of the blood screening business to concentrate on other business units. 

Molecular diagnostics technology is becoming a go-to resource in clinical practice and is the faster-growing part of the healthcare market's diagnostics segment at the present time. Molecular diagnostics tests are being developed constantly, and changes in light of the amount of activity in test development and regulatory and reimbursement challenges in 2013, Kalorama Information presents this updated review of molecular diagnostics with an emphasis on the last six months of 2013: July - December. This report highlights trends and developments that portent the evolution of molecular tests and technologies in the molecular diagnostics testing industry. The ensemble of consumer demand, technological advances and market forces create a dynamic, energetic and fast-moving environment for new molecular diagnostics companies and tests. 

Market analysis in the Molecular Diagnostics Six Month Update covers in vitro diagnostics markets wordlwide, with a bias toward the developed areas of the globe --  North America and Western Europe. Molecular diagnostics testing market segments are broken out, and industry trends and partnerships are given extensive discussion. The Molecular Diagnostics Six Month Update is available at http://www.kaloramainformation.com/Molecular-Diagnostics-Month-7969379/